GSK
2 years ago ⋅ English ⋅ 6 min read
Newsroom
GSK and SCYNEXIS announce an exclusive agreement to commercialise and further develop Brexafemme (ibrexafungerp), a novel, first-in-class medicine to treat fungal infection

For media and investors only- Brexafemme complements GSK’s industry-leading infectious disease portfolio with an FDA approved treatment for vulvovaginal candidiasis- SCYNEXIS will... Read More
GSK
2 years ago ⋅ English ⋅ 7 min read
Newsroom
Medicines Patent Pool signs sublicences with Aurobindo, Cipla and Viatris to produce generic versions of ViiV Healthcare’s innovative long-acting HIV prevention medicine

For media and investors only- Licences should enable potentially millions of people living in areas most impacted by HIV to access this innovative prevention medicine through low-cost g... Read More
GSK
2 years ago ⋅ English ⋅ 7 min read
Newsroom
Phase III RUBY clinical trial demonstrates potential of Jemperli (dostarlimab) plus chemotherapy to redefine the treatment of primary advanced or recurrent endometrial cancer versus chemotherapy alone

For media and investors only- 72% and 36% reduction in the risk of disease progression or death observed in the dMMR/MSI-H population and overall patient population, respectively- Clini... Read More
GSK
2 years ago ⋅ English ⋅ 3 min read
Newsroom
China National Medical Products Administration accepts regulatory submission for Nucala (mepolizumab) in severe eosinophilic asthma

For media and investors onlyGSK plc (LSE/NYSE: GSK) today announced that the China National Medical Products Administration has accepted for review a new drug application for Nucala (me... Read More
GSK
2 years ago ⋅ English ⋅ 4 min read
Newsroom
GSK announces positive pivotal phase III data for 5-in-1 Meningococcal ABCWY vaccine candidate

For media and investors onlyMenABCWY combination vaccine candidate met all its primary endpoints of the pivotal phase III clinical trial and was well tolerated with a safety profile con... Read More
GSK
2 years ago ⋅ English ⋅ 3 min read
Newsroom
US FDA Advisory Committee votes to support effectiveness and safety of GSK’s respiratory syncytial virus older adult vaccine candidate

For media and investors only- Committee votes unanimously that the data support the effectiveness of the vaccine, and 10-2 that the data support the safety of the vaccine- FDA decision... Read More